CL2018001298A1 - Un proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico - Google Patents
Un proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgicoInfo
- Publication number
- CL2018001298A1 CL2018001298A1 CL2018001298A CL2018001298A CL2018001298A1 CL 2018001298 A1 CL2018001298 A1 CL 2018001298A1 CL 2018001298 A CL2018001298 A CL 2018001298A CL 2018001298 A CL2018001298 A CL 2018001298A CL 2018001298 A1 CL2018001298 A1 CL 2018001298A1
- Authority
- CL
- Chile
- Prior art keywords
- corticosteroid
- dry powder
- anticholinergic
- adrenergic
- powder formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
LA INVENCIÓN SE RELACIONA CON UNA FORMULACIÓN EN POLVO SECO PARA INHALACIÓN QUE COMPRENDE UNA COMBINACIÓN DE UN ANTICOLINÉRGICO, UN AGONISTA DE BETA2-ADRENOCEPTOR DE ACCIÓN PROLONGADA, Y UN CORTICOSTEROIDE, Y CON UN PROCESO PARA LA PREPARACIÓN DE LA MISMA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15194660 | 2015-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018001298A1 true CL2018001298A1 (es) | 2018-09-14 |
Family
ID=54548062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018001298A CL2018001298A1 (es) | 2015-11-16 | 2018-05-14 | Un proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico |
Country Status (36)
Country | Link |
---|---|
US (4) | US10086004B2 (es) |
EP (3) | EP3377108B1 (es) |
JP (1) | JP6963548B2 (es) |
KR (1) | KR20180082443A (es) |
CN (1) | CN108289962B (es) |
AR (1) | AR106688A1 (es) |
AU (1) | AU2016356858B2 (es) |
CA (1) | CA3005290A1 (es) |
CL (1) | CL2018001298A1 (es) |
CO (1) | CO2018005141A2 (es) |
CY (3) | CY1123042T1 (es) |
DK (3) | DK3620176T3 (es) |
EA (1) | EA037716B1 (es) |
ES (3) | ES2783855T3 (es) |
GE (1) | GEP20207157B (es) |
HR (3) | HRP20211600T1 (es) |
HU (3) | HUE056441T2 (es) |
IL (1) | IL259329B (es) |
LT (3) | LT3377108T (es) |
MA (3) | MA50487B1 (es) |
MD (3) | MD3377108T2 (es) |
ME (1) | ME03778B (es) |
MX (1) | MX2018005977A (es) |
MY (1) | MY186229A (es) |
PE (1) | PE20181488A1 (es) |
PH (1) | PH12018501022A1 (es) |
PL (3) | PL3620176T3 (es) |
PT (3) | PT3628331T (es) |
RS (3) | RS62506B1 (es) |
SA (1) | SA518391570B1 (es) |
SG (2) | SG10201912093YA (es) |
SI (3) | SI3620176T1 (es) |
TW (1) | TWI731891B (es) |
UA (1) | UA125019C2 (es) |
WO (1) | WO2017085004A1 (es) |
ZA (1) | ZA201803168B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2742376C1 (ru) | 2017-05-11 | 2021-02-05 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик |
KR20220155609A (ko) * | 2017-05-11 | 2022-11-23 | 키에시 파르마슈티시 엣스. 피. 에이. | 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법 |
US11433063B1 (en) | 2019-03-12 | 2022-09-06 | Belhaven Biopharma, Inc. | Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides |
WO2020198716A1 (en) * | 2019-03-27 | 2020-10-01 | Kemin Industries, Inc. | Methods for preparing metal carboxylates in one-pot reaction |
CN112137957B (zh) * | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
WO2021143785A1 (zh) * | 2020-01-15 | 2021-07-22 | 四川海思科制药有限公司 | 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法 |
WO2022045995A1 (en) * | 2020-08-28 | 2022-03-03 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | A process for the preparation of dry powder compositions for inhalation |
US20220304894A1 (en) * | 2021-03-24 | 2022-09-29 | Cmpd Licensing, Llc | Drug powderization within vials |
WO2023117967A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
EP1386630B1 (en) | 2002-07-31 | 2006-05-17 | CHIESI FARMACEUTICI S.p.A. | Powder inhaler |
SI2515855T1 (sl) * | 2009-12-23 | 2014-08-29 | Chiesi Farmaceutici S.P.A. | KOMBINIRANA TERAPIJA ZA KOPB (v angl.: COPD) |
RU2661877C2 (ru) * | 2012-12-06 | 2018-07-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов |
HUE051394T2 (hu) * | 2012-12-06 | 2021-03-01 | Chiesi Farm Spa | Muszkarin receptor antagonista és béta2 adrenerg receptor agonista aktivitással rendelkezõ vegyületek |
US9393202B2 (en) | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
US9402825B2 (en) * | 2013-07-11 | 2016-08-02 | Chiesi Farmaceutici S.P.A. | Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation |
-
2016
- 2016-11-14 EA EA201890966A patent/EA037716B1/ru unknown
- 2016-11-14 RS RS20211283A patent/RS62506B1/sr unknown
- 2016-11-14 JP JP2018524832A patent/JP6963548B2/ja active Active
- 2016-11-14 ES ES16801982T patent/ES2783855T3/es active Active
- 2016-11-14 CA CA3005290A patent/CA3005290A1/en active Pending
- 2016-11-14 RS RS20200440A patent/RS60171B1/sr unknown
- 2016-11-14 DK DK19205980.6T patent/DK3620176T3/da active
- 2016-11-14 ES ES19205980T patent/ES2891073T3/es active Active
- 2016-11-14 SI SI201631331T patent/SI3620176T1/sl unknown
- 2016-11-14 MX MX2018005977A patent/MX2018005977A/es unknown
- 2016-11-14 ES ES19205936T patent/ES2895687T3/es active Active
- 2016-11-14 PL PL19205980T patent/PL3620176T3/pl unknown
- 2016-11-14 SI SI201631349T patent/SI3628331T1/sl unknown
- 2016-11-14 PE PE2018000973A patent/PE20181488A1/es unknown
- 2016-11-14 EP EP16801982.6A patent/EP3377108B1/en active Active
- 2016-11-14 HU HUE19205980A patent/HUE056441T2/hu unknown
- 2016-11-14 PT PT192059368T patent/PT3628331T/pt unknown
- 2016-11-14 MD MDE20180917T patent/MD3377108T2/ro unknown
- 2016-11-14 MA MA50487A patent/MA50487B1/fr unknown
- 2016-11-14 MD MDE20200899T patent/MD3620176T2/ro unknown
- 2016-11-14 MA MA50488A patent/MA50488B1/fr unknown
- 2016-11-14 RS RS20211196A patent/RS62404B1/sr unknown
- 2016-11-14 WO PCT/EP2016/077558 patent/WO2017085004A1/en active Application Filing
- 2016-11-14 UA UAA201805271A patent/UA125019C2/uk unknown
- 2016-11-14 SG SG10201912093YA patent/SG10201912093YA/en unknown
- 2016-11-14 DK DK16801982.6T patent/DK3377108T3/da active
- 2016-11-14 EP EP19205936.8A patent/EP3628331B1/en active Active
- 2016-11-14 LT LTEP16801982.6T patent/LT3377108T/lt unknown
- 2016-11-14 PT PT168019826T patent/PT3377108T/pt unknown
- 2016-11-14 KR KR1020187013286A patent/KR20180082443A/ko unknown
- 2016-11-14 AU AU2016356858A patent/AU2016356858B2/en active Active
- 2016-11-14 MA MA43256A patent/MA43256B1/fr unknown
- 2016-11-14 HU HUE19205936A patent/HUE056260T2/hu unknown
- 2016-11-14 DK DK19205936.8T patent/DK3628331T3/da active
- 2016-11-14 HR HRP20211600TT patent/HRP20211600T1/hr unknown
- 2016-11-14 LT LTEP19205936.8T patent/LT3628331T/lt unknown
- 2016-11-14 PT PT192059806T patent/PT3620176T/pt unknown
- 2016-11-14 SI SI201630682T patent/SI3377108T1/sl unknown
- 2016-11-14 EP EP19205980.6A patent/EP3620176B1/en active Active
- 2016-11-14 ME MEP-2020-80A patent/ME03778B/me unknown
- 2016-11-14 CN CN201680066801.5A patent/CN108289962B/zh active Active
- 2016-11-14 AR ARP160103473A patent/AR106688A1/es unknown
- 2016-11-14 PL PL16801982T patent/PL3377108T3/pl unknown
- 2016-11-14 SG SG11201804050QA patent/SG11201804050QA/en unknown
- 2016-11-14 MD MDE20200898T patent/MD3628331T2/ro unknown
- 2016-11-14 HR HRP20211598TT patent/HRP20211598T1/hr unknown
- 2016-11-14 MY MYPI2018000704A patent/MY186229A/en unknown
- 2016-11-14 TW TW105137048A patent/TWI731891B/zh active
- 2016-11-14 HU HUE16801982A patent/HUE049751T2/hu unknown
- 2016-11-14 LT LTEP19205980.6T patent/LT3620176T/lt unknown
- 2016-11-14 GE GEAP201614783A patent/GEP20207157B/en unknown
- 2016-11-14 PL PL19205936T patent/PL3628331T3/pl unknown
- 2016-11-15 US US15/351,562 patent/US10086004B2/en active Active
-
2018
- 2018-05-14 IL IL259329A patent/IL259329B/en active IP Right Grant
- 2018-05-14 ZA ZA2018/03168A patent/ZA201803168B/en unknown
- 2018-05-14 CL CL2018001298A patent/CL2018001298A1/es unknown
- 2018-05-14 SA SA518391570A patent/SA518391570B1/ar unknown
- 2018-05-15 PH PH12018501022A patent/PH12018501022A1/en unknown
- 2018-05-16 CO CONC2018/0005141A patent/CO2018005141A2/es unknown
- 2018-08-27 US US16/113,026 patent/US10772896B2/en active Active
-
2020
- 2020-04-01 HR HRP20200537TT patent/HRP20200537T1/hr unknown
- 2020-04-06 CY CY20201100319T patent/CY1123042T1/el unknown
- 2020-08-07 US US16/987,695 patent/US10966991B2/en active Active
-
2021
- 2021-02-24 US US17/184,181 patent/US11628175B2/en active Active
- 2021-09-07 CY CY20211100793T patent/CY1124475T1/el unknown
- 2021-09-09 CY CY20211100797T patent/CY1124490T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018001298A1 (es) | Un proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico | |
CO2018005139A2 (es) | Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico | |
MX2016013280A (es) | Composiciones topicas para el alivio del dolor, manufactura y uso. | |
MX2017003131A (es) | Metodo para la preparacion de 2-alcoxi ciclohexanol. | |
MX2018005784A (es) | Mezcla hemostatica de fibras cortas y largas basadas en celulosa. | |
IN2014CH00840A (es) | ||
EA201691924A1 (ru) | Фармацевтические композиции | |
UY35823A (es) | Profármacos de antagonista de nmda | |
CL2018003338A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant. | |
NZ721832A (en) | Solid forms of tenofovir | |
DOP2018000032A (es) | Composición herbicida y proceso para prepararla | |
EA201692453A1 (ru) | Способ получения ингаляционных составов | |
EA201692428A1 (ru) | Способ получения сухих порошкообразных составов | |
MX2016016612A (es) | Formulaciones estables de undecanoato de testosterona. | |
UA114469U (xx) | ЗАСТОСУВАННЯ ПРЕПАРАТУ КАПІКОРУ (МЕЛЬДОНІЮ ДИГІДРАТУ І γ -БУТИРОБЕТАЇНУ ДИГІДРАТУ) ЯК НЕФРОПРОТЕКТОРНОГО ЗАСОБУ | |
TH1601000099A (th) | สูตรผสมผงแห้งที่ประกอบรวมด้วยแอนติโคลิเนอร์จิก, คอร์ติโคสเตียรอยด์ และเบตา-แอดรีเนอร์จิกสำหรับการให้โดยการสูด | |
EA201692427A1 (ru) | Новый способ получения сухих порошкообразных составов | |
UY35956A (es) | Formulación de atazanavir y cobicistat para el tratamiento del vih | |
TH1501004020A (th) | สูตรผสม, การเตรียมและการใช้เชื้อเพลิงชีวภาพมีพื้นฐานกลีเซอรอล | |
CO6990724A2 (es) | Proceso para la preparación de magnolol y derivados del mismo | |
TH1501005391A (th) | องค์ประกอบทางเภสัชกรรมแบบผงละเอียด |